Showing results (171-180 of 1,150) with videos related to
Sort By:
Pageof 115
BMC Medicine|February 18, 2019
Correction to: A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placeboMichael Berk, Alyna Turner, Gin S Malhi, et al.The Journal of Clinical Psychiatry|November 13, 2009
Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapineDavid de Lucena, Brisa Simões Fernandes, Michael Berk, et al.BMC Medicine|January 26, 2019
A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placeboMichael Berk, Alyna Turner, Gin S Malhi, et al.Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology|April 29, 2023
The Impact of N-acetylcysteine on Major Depression: Qualitative Observation and Mixed Methods Analysis of Participant Change during a 12-week Randomised Controlled TrialSamantha E Russell, David R Skvarc, Mohammadreza Mohebbi, et al.Human Psychopharmacology|October 31, 2002
In vitro metabolism of mirtazapine enantiomers by human cytochrome P450 enzymesSeetal Dodd, David W. Boulton, Graham D. Burrows, et al.Journal of Affective Disorders|July 2, 2011
The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trialMichael Berk, Olivia Dean, Sue M Cotton, et al.Journal of Affective Disorders|July 16, 2017
Indices of insulin resistance and glucotoxicity are not associated with bipolar disorder or major depressive disorder, but are differently associated with inflammatory, oxidative and nitrosative biomarkersKamila Landucci Bonifácio, Décio Sabbatini Barbosa, Estefânia Gastaldello Moreira, et al.Pageof 115